Sgmo holding up well and great news flow ... tho rough market
I guess Sangamo will need a new pipeline slide including Solid organ transplant TX200 in their presentation on 4/1/21. It seems to me there has been validating news flow in sickle/b-thal, Alzheimer’s, fabry, now tx200, all in the past few weeks. This board rightly complains that the pipeline was moving very slowly. The last few weeks were basically upside surprises, the most encouraging being the sickle news, but I also liked seeing that for the preclinical Alzheimer’s program they are collaborating with a lab at Harvard, with senior author Bradley Hyman, who directs the Alzheimer’s disease research unit at the MassGeneral Institute for Neurodegenerative Disease and said “The technology worked just the way we had hoped — reducing tau substantially for as long as we looked, causing no side effects that we could see even over many, many months, and improving the pathological changes in the brains of the animals”. Seems like validation across several programs as many competitors trying to work in these areas, ions, biomarin, srpt, and others have been getting mediocre results. I haven’t been watching the many competitors in the space, there are clearly a few that are looking great such as FATE (a crazy good call by bct that I didn’t take advantage of in the low teens when it was being talked about here last year only to pick up a nominal position around here) but as far as I know, there aren’t any companies with comparable pipelines that have similar market caps. Maybe the closest looking small cap pipeline wise (though I know this is a very questionable assertion to say the least) would be crsp which has an 8 BB market cap after being cut in half from 220 to 110 on this biotech correction. I think as bct has been saying the fundamentals and technicals have never been more aligned, time to buy and hold on. The best of biotech/bio (per cathie wood to name a few of her arkg picks crsp fate Bli Pacb beam iova psnl nvta vcyt) are crushed.... actually Sgmo is holding up well... I think we start going back up within a week or so with a run up into earning season. All the risk in this stock is market risk and sector arkg/Xbi and tax/spend policies.... I think the chart on Xbi arkg and Sgmo look very good, but curious what the chartists think about Xbi arkg and Sgmo. People sitting on cash can look also at nndm, open, fate, nvta, sklz, all the 3D printers including aone, spfr, ddd. I have used the recent down moves to diversify but will continue to hold a large Sgmo position here. Appreciate the recent more civil tone here and all the good info. Shout out to poster sangamo for the tx200 news today! Thank you. Good luck to all.